{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:07:30Z","timestamp":1779512850801,"version":"3.53.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cpcardiol.2026.103335","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:47:27Z","timestamp":1774396047000},"page":"103335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of mineralocorticoid receptor antagonists in cardiovascular, renal and metabolic disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Charalampos","family":"Filippatos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Kourek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Boutsikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos-Iason","family":"Tepetes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Kostakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodosios","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Xanthopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto Ruiz","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9670","authenticated-orcid":false,"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.cpcardiol.2026.103335_bib0001","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10458","key":"10.1016\/j.cpcardiol.2026.103335_bib0002","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103335_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103335_bib0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103335_bib0005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103335_bib0006","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1038\/s41467-025-64640-3","article-title":"Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpcardiol.2026.103335_bib0007","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2026.103335_bib0008","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103335_bib0009","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.3390\/jcm14093213","article-title":"Finerenone: potential clinical application across the spectrum of cardiovascular disease and chronic kidney disease","volume":"14","author":"Haq","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2026.103335_bib0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2021.12.027","article-title":"Real world comparison of spironolactone and eplerenone in patients with heart failure","volume":"97","author":"Pardo-Mart\u00ednez","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"27","key":"10.1016\/j.cpcardiol.2026.103335_bib0011","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103335_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102615","article-title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials","volume":"49","author":"Pamporis","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"34","key":"10.1016\/j.cpcardiol.2026.103335_bib0013","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/eurheartj\/ehaf316","article-title":"Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial","volume":"46","author":"Berger","year":"2025","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103335_bib0014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/biomedicines9040441","article-title":"Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology","volume":"9","author":"Pereira","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103335_bib0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12872-024-04103-7","article-title":"Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis","volume":"24","author":"Elshahat","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103335_bib0016","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.3390\/jcm12123992","article-title":"Questions and answers-the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist","volume":"12","author":"L","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2026.103335_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1476029","article-title":"A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist","volume":"11","author":"Zhai","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103335_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70075","article-title":"Finerenone in Chronic Kidney disease: a comprehensive review of mechanisms, efficacy and safety","volume":"41","author":"Hu","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103335_bib0019","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal benefits of finerenone: protecting kidney and heart","volume":"55","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103335_bib0020","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/s12872-025-05098-5","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103335_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"37","key":"10.1016\/j.cpcardiol.2026.103335_bib0022","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103335_bib0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12882-025-04710-2","article-title":"Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials","volume":"27","author":"Muhammad Daniyal","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cpcardiol.2026.103335_bib0024","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S0735-1097(25)02150-3","article-title":"Effects of sodium glucose cotransporter 2 inhibitors on the risk of hyperkalemia in patients on mineralocorticoid receptor antagonist: a systematic review and meta-analysis","volume":"85","author":"Cordovez","year":"2025","journal-title":"JACC"},{"issue":"19","key":"10.1016\/j.cpcardiol.2026.103335_bib0025","first-page":"1460","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized","volume":"145","author":"Neuen","year":"2022","journal-title":"Control Trials Circ"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103335_bib0026","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103335_bib0027","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3390\/biomedicines13071693","article-title":"Current application of mineralocorticoid antagonist (MRA) in heart failure and CKD: does non-steroidal drug add novel insights","volume":"13","author":"Carlino","year":"2025","journal-title":"Biomedicines"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:46:25Z","timestamp":1779511585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280626000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0146280626000770"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103335","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of mineralocorticoid receptor antagonists in cardiovascular, renal and metabolic disease","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103335"}}